血清转化生长因子、碱性磷酸酶、前列腺特异性抗原与转移性去势抵抗型前列腺癌的相关性分析

Correlations of serum transforming growth factor，alkaline phosphatase，and prostate-specific antigen with metastatic castration-resistant prostate cancer

摘要:

目的 探讨前列腺癌骨转移患者血清中转化生长因子-β1（transforming growth factor-β1，TGF-β1）、碱性磷酸酶（alkaline phosphatase，ALP）、前列腺特异抗原（prostate specific antigen，PSA）与患者发生转移性去势抵抗性前列腺癌（metastatic castration-resistant prostate cancer，mCRPC）的相关性。方法 根据回顾性研究的方法，选择2022年1月至2023年2月广东省中医院确诊为前列腺癌骨转移的患者为研究对象，根据是否发生CRPC分为2组，CRPC组26例，非CRPC组29例。收集患者一般资料，并通过酶联免疫吸附实验测定患者血清TGF-β1、ALP、PSA的水平进行分析。结果 在2组单因素比较中，血清PSA的差异没有统计学意义（Ρ>0.05），血清TGF-β1、ALP的差异具有统计学意义（Ρ<0.05）。二元logistic回归分析显示，TGF-β1是CRPC发生的独立危险因素。Spearman相关性分析显示，在CRPC患者血清中TGF-β1和ALP水平呈正相关。结论 TGF-β1及ALP水平与前列腺癌骨转移患者疾病侵袭和进展密切相关，可能为前列腺癌骨转移患者治疗及预后提供评估依据。

Abstract:

Objective To investigate the correlations of serum transforming growth factor（TGF）-β1，prostate-specific antigen（PSA），and alkaline phosphatase（ALP） with the occurrence of metastatic castration-resistant prostate cancer（mCRPC） in patients with prostate cancer bone metastases.Methods Using the method of retrospective study，patients diagnosed with bone metastasis of prostate cancer in Guangdong Provincial Hospital of Chinese Medicine from January 2022 to February 2023 were selected and divided into CRPC group（26 cases） and non-CRPC group（29 cases）. The general information of patients was collected，and the levels of serum TGF-β1，ALP，and PSA were measured using enzyme-linked immunosorbent assay.Results Univariate analysis was performed between the two groups. The difference in serum PSA was not significant（P>0.05），while the differences in serum TGF-β1 and ALP were statistically significant（P<0.05）. Binary logistic regression analysis showed that TGF-β1 was an independent risk factor for the occurrence of mCRPC. Spearman correlation analysis showed a positive correlation between serum TGF-β1 and ALP in patients with mCRPC.Conclusion TGF-β1 and ALP levels are closely related to the invasion and progression of prostate cancer bone metastases. Our results may provide a basis for evaluating the treatment and prognosis of patients with prostate cancer bone metastases.